

HCCFA

< Selective Inhibitor of AKR1B10 >

For more information : http://www.funakoshi.co.jp/exports_contents/80996

HCCFA is a new, potent and selective Inhibitor of Aldo-Keto Reductase family member 1B10 (AKR1B10).

Background of HCCFA

AKR1B10 is a NADPH dependent reductase, and involved in metabolism of retinoid and isoprenoid. After high expression of AKR1B10 in non-small cell lung cancer (NSCLC) was reported in 2005, such high expression was also found in many kinds of cancer including liver cancer, uterus cancer and bile duct cancer. Therefore, AKR1B10 inhibitor is noted as a new target of anti-cancer drug development.

AKR1B10 shows 70.6% homology in amino-acid sequence to aldose reductase (AKR1B1, or AR), and both have similar structure and substrate specificity. Since conventional inhibitors for AKR1B10 also inhibit AR to the same degree, a selective inhibitor against AKR1B10 or AR has been awaited.

HCCFA is a new compound which selectively and strongly inhibits AKR1B10.

This product has been commercialized with the support of both the University of Toyama and Gifu Pharmaceutical University.


Reference : Endo S., *et al.*, *J. Med. Chem.*, **60**:8441-8445 (2017).

Features

- Selective and strong inhibitor of AKR1B10.
- Low inhibitory potency to AKR1B1 (AR, aldose reductase)
- Compatible to *in vitro* and *in vivo* use (not for human or veterinary use)

Chemical Information

- Chemical Name: 7-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid [3-(4-fluorophenyl)propyl] amide
- Alternate Name: *N*-[3-(4-fluorophenyl)propyl]-7-hydroxy-2-oxo-2H-1-Benzopyran-3-carboxamide
- CAS No.: 2136579-33-2
- Molecular Formula: C₁₉H₁₆FNO₄
- Molecular Weight: 341.33
- Melting Point: 207-209°C (Ethanol)
- Solubility: Soluble in DMSO
- Purity: >98% by HPLC



Product Information

[Manufacturer : FNA]

| Product Name | Size | Catalog # | Storage |
|---------------------------|------|-----------|---------|
| HCCFA <AKR1B10 Inhibitor> | 1 mg | FDV-0016 | -20 °C |




Fig.1 Inhibitory activity of HCCFA

Inhibitory activity of HCCFA was measured by using recombinant AKR1B10 or AR. HCCFA inhibits AKR1B10 strongly and selectively.




Fig.2 Recovery of CDDP susceptibility

A549 cells or CDDP-R-A549 cells (cisplatin-resistant A549 cells) were treated with 0 to 40 µM of HCCFA for 2 hours and cultured for 24 hours under culture media containing 40 µM of CDDP (cisplatin). HCCFA recovers CDDP susceptibility of CDDP-R-A549 cells in a dose-dependent manner.

* p<0.05 vs CDDP-R-A549 cells with 40 µM CDDP alone




Fig.3 Inhibition of proliferation and metastasis of cancer cells

Luciferase expressing A549-Luc cells were cultured in DMSO (control) or 20 µM HCCFA containing medium for 24 hours, and transferred to BALB/c nude mouse by tail vein injection. After 4 days, luminescent in lung was observed. Data shows that HCCFA inhibits proliferation and metastasis of A549 cells *in vivo*.

NOTE

※ All products here are research use only, not for diagnostic use.
 ※ Specs might be changed for improvement without notice.

※ Company name and product name are trademark or registered mark.
 ※ Please contact your local distributors for orders, quote request and inquiry.

Your Local Distributor

Funakoshi Co., Ltd.

Address: 9-7 Hongo 2-Chome, Bunkyo-ku, Tokyo 113-0033 JAPAN
 Phone : +81-3-5684-6296
 Fax : +81-3-5684-6297
 Email : export@funakoshi.co.jp